Treatment

TNG908, TNG908, TNG908, TNG908, MIDAZOLAM clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
This study is testing a new drug, TNG908, for people with advanced cancers that have a specific genetic change called MTAP-deleted. It aims to see if the drug is safe, what dose works best, and if it can help shrink tumours.
For: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors · •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) · A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC
France